Extended-release gabapentin in post-herpetic neuralgia

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 16, 2011, Pages 2565-2571

  Thomas, Ben ^a   Farquhar Smith, Paul ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

acuform; DM 1796; extended release gabapentin; gabapentin; gralise; post herpetic neuralgia

Indexed keywords

ACUFORM; GABAPENTIN; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MANUFACTURE; DRUG TOLERABILITY; EVENING DOSAGE; EXTENDED DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDLINE; PAIN ASSESSMENT; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SYNAPTOGENESIS; SYSTEMATIC REVIEW;

AMINES; ANALGESICS, NON-NARCOTIC; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEURALGIA, POSTHERPETIC;

EID: 80054060637     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.622267     Document Type: Article

References (28)

1. Doggrel SA. Pregabalin or morphine and gabapentin for neuropathic pain. Expert Opin Pharmacother 2005;12:2535-9
2. Bader MS, McKinsey DS. Viral infections in the elderly: the challenges of managing herpes zoster, influenza, and RSV. Postgrad Med 2005;118:45-54 (Pubitemid 43161303)
3. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Centre for Reviews and Dissemination 2004. NHS Economic Evaluation Database. Available from: CRDWeb/ShowRecord.asp?View=Full&ID=22001006577 [Last accessed 18 September 2011]
4. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997;13:327-31 (Pubitemid 27280025)
5. Guidelines from the US Agency for Healthcare Research and Quality. Available from: . gov/content.aspx?id=11724 [Last accessed 17 August 2011]
6. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51 (Pubitemid 350051570)
7. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
8. Attal N, Cruccu G, Baron R, et al. The European Federation of Neurological Societies guidelines for the pharmacological treatment of neuropathic pain. 2010 revision. Eur J Neurol 2010;17:1113-23
9. Eroglu C, Allen NJ, Susman MW. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139:380-92
10. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharma Res 1993;10:276-81 (Pubitemid 23041744)
11. Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther 2008;30:909-16 (Pubitemid 351799872)
12. Gusler G, Berner B, Chau M, Padua A. Optimal polymer mixtures for gastric retentive tablets. 2004;US6723340
13. Berner B, Louie Helm J. Tablet shapes to enhance gastric retention of swellable controlled release oral dosage forms. 2002;US6488962
14. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig 2002;30:765-76
15. Jensen MP, Chiang YK, Wu J. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia. Clin J Pain 2009;25:286-92
16. Irving G, Jensen M, Cramer M, et al. Efficacy and tolerability of gastric-retentive gabapentin for the treatment of postherpetic neuralgia: results of a double-blind, randomized, placebo-controlled clinical trial. Clin J Pain 2009;25:185-92
17. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51:346-58
18. Sang CN, Sathyanarayana R, Carter FJ, Sweeney M. Extended release for the once-daily treatment of post herpetic neuralgia. Poster presented at the International Association for the Study of Pain, 13th World Congress on Pain; 29 August - 2 September 2010; Montreal, Canada
19. Sweeney M, Sathyanarayana R. Efficacy and tolerability of once-daily gabapentin for the treatment of postherpetic neuralgia in patients at least 65 years old. Poster presented at the Society of General Internal Medicine 34th Annual Meeting; 4 - 7 May 2011; Phoenix, AZ, USA
20. ARUP Laboratory Test Directory. National Reference Laboratory. Gabapentin. Available from: . aruplab.com/guides/ug/tests/0090057.jsp [Last accessed 19 September 2011]
21. Liu-Seifert H, Shuyu Zhang S, D'Souza D, et al. A closer look at the baseline-observation-carried-forward (BOCF). Patient Prefer Adherence 2010;4:11-16
22. Saha C, Jones M. Bias in the last observation carried forward method under informative dropout. J Stat Plan Inference 2009;139:246-55
23. Summary of NDA 22-516 Cymbalta for Treatment of Chronic Pain. FDA Public Health Advisory. Washington, DC:FDA/Center for Drug Evaluation and Research, 2010. Available from: [Last accessed 19 September 2011]
24. Depomed Press Release. Depomed will engage in mediation to resolve dispute with Abbott; Comments on DM-1796 regulatory status and orphan drug designation. Available from: = [Last accessed 19 September 2011]
25. Depomed Press Release. Depomed announces receipt of a $48 million milestone payment for the approval of GRALISE(TM). Available from: = [Last accessed 19 September 2011]
26. Depomed Press Release. Depomed announces US Food and Drug Administration approval of GRALISE(TM) (gabapentin) once-daily tablets for treatment of post-herpetic neuralgia. Available from: = [Last accessed 19 September 2011]
27. Wesche D, Bockbrader H. A pharmokinetic comparison of pregabalin and gabapentin. J Pain 2007;6:S29
28. Attal N, Cruccu G, Baron R, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23